27-Oct-2026 13:45:19
MOREPENLABGeneral news
MOREPEN LABORATORIES Q2: REVENUE SURGES 81% YOY; EBITDA JUMPS 273%, PAT UP 117%
• Revenue: Up 81% YoY to ₹755 Cr, supported by strong CDMO growth and improving business mix • EBITDA: Surged 273% YoY to ₹132 Cr, driven by higher operating leverage • Net Profit: Up 117% YoY to ₹89 Cr • EBITDA Margin: Expanded to 17.45%, reflecting improved profitability • CDMO Business: Revenue stood at ₹253 Cr, contributing 52% of combined API and CDMO revenue • Exports: Surged 131% YoY to ₹397 Cr, supported by international demand • Medical Devices: Revenue increased 65% YoY to ₹208 Cr • Growth Drivers: Scale-up of commercial CDMO supplies, improving product mix and higher operating leverage supported performance
MOREPEN LABORATORIES LTD.